Log In
Print
BCIQ
Print
Print this Print this
 

Lambrolizumab (MK-3475)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionHumanized IgG4 mAb against PD-1 receptor (PDCD1; PD-1; CD279)
Molecular Target PD-1 receptor (PDCD1) (PD-1) (CD279)
Mechanism of ActionAntibody
 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of Development
More More
 Archive Items are loading loading
Get a free BioCentury trial today